Reference health
Prostaglandins in migraine
79/79 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 79 checked references that resolve
resolves10.1113/jphysiol.1936.sp003433
On the specific vaso‐dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin)
resolves10.1038/newbio231232a0
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
resolves10.1111/j.0954-6820.1968.tb10502.x
CLINICAL AND METABOLIC EFFECTS OF DIFFERENT DOSES OF PROSTAGLANDIN E<sub>1</sub> IN MAN
resolves10.3390/ph3061966
NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data
resolves10.1111/j.1526-4610.2008.01064.x
Triptans vs Other Drugs for Acute Migraine. Are There Differences in Efficacy? A Comment
resolves10.1016/S1474-4422(09)70090-0
Origin of pain in migraine: evidence for peripheral sensitisation
resolves10.1097/01.WCB.0000139446.61789.14
EP
<sub>1</sub>
- and EP
<sub>3</sub>
-Receptors Mediate Prostaglandin E
<sub>2</sub>
–Induced Constriction of Porcine Large Cerebral Arteries
resolves10.1038/sj.bjp.0705645
EP<sub>4</sub> prostanoid receptor‐mediated vasodilatation of human middle cerebral arteries
resolves10.1111/j.1476-5381.2009.00027.x
BGC20‐1531, a novel, potent and selective prostanoid EP<sub>4</sub>receptor antagonist: a putative new treatment for migraine headache
resolves10.1111/j.1365-2125.1979.tb00914.x
Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man.
resolves10.1016/j.vph.2011.06.004
Pharmacological and expression profile of the prostaglandin I2 receptor in the rat craniovascular system
resolves10.1203/00006450-199811000-00016
Responsiveness of Human Infant Cerebral Arteries to Sympathetic Nerve Stimulation and Vasoactive Agents
resolves10.1016/S0167-0115(99)00030-0
Interleukin-1β potentiates endothelin ETB receptor-mediated contraction in cultured segments of human temporal artery
resolves10.1046/j.1365-2125.1999.00985.x
Inhibition of vasoconstriction by the thromboxane A<sub>2</sub> antagonist GR32191B in the human radial artery
resolves10.1161/01.HYP.19.6.739
Signal transduction pathways in constriction of the basilar artery in vivo.
resolves10.1161/01.STR.6.3.293
Constriction of Pial Arterioles Produced by Prostaglandin F
<sub>2α</sub>
resolves10.1016/0090-6980(83)90154-5
The effect of PGF2a on in vivo cerebral arteriolar diameter in cats and rats
resolves10.3988/jcn.2012.8.2.89
Sensitization of the Trigeminovascular Pathway: Perspective and Implications to Migraine Pathophysiology
resolves10.1038/sj.bjp.0707149
Intraplantar PGE<sub>2</sub> causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases
resolves10.1016/S0304-3959(01)00487-0
Spinal administration of prostaglandin E2 or prostaglandin F2α primarily produces mechanical hyperalgesia that is mediated by nociceptive specific spinal dorsal horn neurons
resolves10.1016/0006-8993(90)90723-O
Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2α to conscious mice
resolves10.1016/S0090-6980(00)00101-5
Expression and regulation of prostaglandin E receptor subtype mRNAs in rat sensory ganglia and spinal cord in response to peripheral inflammation
resolves10.1016/j.neulet.2011.03.046
Contribution of peripheral versus central EP1 prostaglandin receptors to inflammatory pain
resolves10.1124/jpet.106.105569
Prostaglandin E2 Receptor EP4 Contributes to Inflammatory Pain Hypersensitivity
resolves10.1016/0306-4522(94)90483-9
Distribution of the messenger rna for the prostaglandin e receptor subtype ep3 in the mouse nervous system
resolves10.1046/j.1460-9568.1999.00682.x
Distribution, regulation and colocalization of the genes encoding the EP<sub>2</sub>‐ and EP<sub>4</sub>‐PGE<sub>2</sub> receptors in the rat brain and neuronal responses to systemic inflammation
resolves10.1016/j.neulet.2011.10.050
Prostaglandin E2 receptor expression in the rat trigeminal-vascular system and other brain structures involved in pain
resolves10.1016/S1471-4914(02)02383-3
Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets
resolves10.1016/j.lfs.2009.10.018
Acute and persistent nociceptive paw sensitisation in mice: The involvement of distinct signalling pathways
resolves10.1126/science.1094925
GlyR α3: An Essential Target for Spinal PGE
<sub>2</sub>
-Mediated Inflammatory Pain Sensitization
resolves10.1111/j.1749-6632.1998.tb09567.x
Pain Modulatory Actions of Cytokines and Prostaglandin E<sub>2</sub> in the Brain
resolves10.1016/0006-8993(94)91275-0
Intracerebroventricular injection of prostaglandin E2 induces thermal hyperalgesia in rats: the possible involvement of EP3 receptors
resolves10.1046/j.1471-4159.2001.00613.x
Effects of selective COX‐1 and ‐2 inhibition on formalin‐evoked nociceptive behaviour and prostaglandin E<sub>2</sub> release in the spinal cord
resolves10.1111/j.1365-2125.1987.tb03242.x
Inflammatory responses to intradermal injection of platelet activating factor, histamine and prostaglandin E2 in healthy volunteers: a double blind investigation.
resolves10.1016/0006-8993(89)90928-1
Prostaglandin effects after elimination of indirect hyperalgesic mechanisms in the skin of the rat
resolves10.1016/0306-4522(91)90255-M
Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia
resolves10.1124/jpet.107.123745
Sensitization and Activation of Intracranial Meningeal Nociceptors by Mast Cell Mediators
resolves10.1186/1744-8069-1-3
Sensitization of TRPV1 by EP<sub>1</sub> and IP Reveals Peripheral Nociceptive Mechanism of Prostaglandins
resolves10.1016/S1388-1981(99)00164-X
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs
resolves10.1016/0304-3959(92)90166-9
Allodynia evoked by intrathecal administration of prostaglandin F2α to conscious mice
resolves10.1016/0304-3959(94)00183-F
Nitric oxide mediates allodynia induced by intrathecal administration of prostaglandin E2 or prostaglandin F2α in conscious mice
resolves10.1016/0306-4522(93)90272-H
Sensitization of peripheral afferent fibres in the in vitro neonatal rat spinal cord-tail by bradykinin and prostaglandins
resolves10.1038/sj.bjp.0701853
Characterization of prostanoid receptor‐evoked responses in rat sensory neurones
resolves10.1177/0333102409357957
Functional and molecular characterization of prostaglandin E
<sub>2</sub>
dilatory receptors in the rat craniovascular system in relevance to migraine
resolves10.1016/S0306-4522(98)00366-2
Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro
resolves10.1038/sj.bjp.0704357
Characterization of the prostanoid receptor types involved in mediating calcitonin gene‐related peptide release from cultured rat trigeminal neurones
resolves10.1016/j.neulet.2004.05.067
Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro
resolves10.1038/nrneurol.2010.127
CGRP and its receptors provide new insights into migraine pathophysiology
resolves10.1016/j.clpt.2004.10.001
BIBN4096BS Antagonizes Human α-calcitonin Gene Related Peptide–induced Headache and Extracerebral Artery Dilatation*
resolves10.1111/j.1526-4610.2006.00485.x
Mast Cell Involvement in the Pathophysiology of Migraine Headache: A Hypothesis
resolves10.1016/j.pain.2007.03.012
Mast cell degranulation activates a pain pathway underlying migraine headache
resolves10.4049/jimmunol.129.4.1627
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE.
resolves10.1016/0005-2760(79)90020-1
Prostaglandin, thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells
resolves10.1136/ard.57.1.25
Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro
resolves10.1111/j.1526-4610.2010.01657.x
Changes in Salivary Prostaglandin Levels During Menstrual Migraine With Associated Dysmenorrhea
resolves10.1111/j.1526-4610.1989.hed2908498.x
Increase in PGE
<sub>2</sub>
and TXA
<sub>2</sub>
in the Saliva of Common Migraine Patients. Action of Calcium Channel Blockers
resolves10.1046/j.1468-2982.2000.00146.x
Nitric Oxide Metabolites, Prostaglandins and Trigeminal Vasoactive Peptides in Internal Jugular Vein Blood During Spontaneous Migraine Attacks
resolves10.1136/adc.63.3.342-a
Increased main urinary metabolite of prostaglandin F2 alpha excretion in childhood migraine.
resolves10.1111/j.1468-2982.2008.01748.x
Prostaglandin E
<sub>2</sub>
(PGE
<sub>2</sub>
) Induces Headache in Healthy Subjects
resolves10.1177/0333102410373156
Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D
<sub>2</sub>
(PGD
<sub>2</sub>
)
resolves10.1177/0333102411423314
Pro-inflammatory and vasoconstricting prostanoid PGF
<sub>2α</sub>
causes no headache in man
resolves10.1177/0333102412451360
Prostaglandin E
<sub>2</sub>
induces immediate migraine-like attack in migraine patients without aura
resolves10.1111/j.1468-2982.2009.01923.x
Prostaglandin I
<sub>2</sub>
(epoprostenol) triggers migraine-like attacks in migraineurs
resolves10.1074/jbc.M011408200
Prostaglandin Receptor Subtypes, EP3C and EP4, Mediate the Prostaglandin E2-induced cAMP Production and Sensitization of Sensory Neurons
resolves10.1124/jpet.107.122010
CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4 Receptor Antagonist with Antihyperalgesic Properties
resolves10.1007/s10194-011-0358-9
The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache
The 3 references without a DOI — listed, not checked
no DOI — not checkedR22-7-20130430
no DOI — not checkedR72-7-20130430
no DOI — not checkedR73-7-20130430
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1097/wco.0b013e328360864b"><img src="https://citestamp.com/citestamped/10.1097/wco.0b013e328360864b/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1097/wco.0b013e328360864b)